CD274 and non-small cell lung carcinoma: Early results for bintrafusp alfa (a bifunctional fusion protein of the extracellular domain of the type 2 TGFβ receptor fused to an anti-PD-L1 antibody) showed promising efficacy and manageable toxicity in NSCLC patients previously treated with platinum-based immunotherapy (101).